Nintedanib

Drug Profile

Nintedanib

Alternative Names: BIBF-1120; Intedanib; Ofev; Vargatef

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Acetamides; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Idiopathic pulmonary fibrosis; Systemic scleroderma; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Non-small cell lung cancer
  • Phase III Colorectal cancer; Mesothelioma; Ovarian cancer; Systemic scleroderma
  • Phase II Bladder cancer; Endometrial cancer; Hepatocellular carcinoma; Renal cell carcinoma
  • Phase I Fallopian tube cancer; Peritoneal cancer; Solid tumours
  • No development reported Multiple myeloma
  • Discontinued Prostate cancer

Most Recent Events

  • 19 Dec 2016 Boehringer Ingelheim plans a phase III trial for Interstitial lung diseases in Argentina, Belgium, Canada, Chile, China, France, Germany, Italy, Japan, Poland, Russia, Spain, South Korea, USA and United Kingdom (PO) (NCT02999178)
  • 14 Dec 2016 Nintedanib receives Orphan Drug status for Mesothelioma in USA
  • 09 Dec 2016 Boehringer Ingelheim terminates a phase II trial in Colorectal cancer (Monotherapy, Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (NCT02780700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top